Diabetic Retinopathy Market Size, Share, Growth, and Industry Analysis, By Type (Laser surgery,Injection of corticosteroids,Anti-VEGF drugs into the eye,Vitrectomy), By Application (NON-IVT Therapy,IVT Therapy), Regional Insights and Forecast to 2035

Diabetic Retinopathy Market Overview

The global Diabetic Retinopathy Market is forecast to expand from USD 9585.65 million in 2026 to USD 10315.12 million in 2027, and is expected to reach USD 18553.16 million by 2035, growing at a CAGR of 7.61% over the forecast period.

The global Diabetic Retinopathy Market is rapidly expanding due to the increasing prevalence of diabetes and the rising demand for early diagnostic and therapeutic solutions. Over 93 million people globally are affected by diabetic retinopathy, and the number is increasing annually. Proliferative diabetic retinopathy impacts nearly 17 million patients worldwide. In 2025, over 32% of diagnosed diabetics are projected to exhibit signs of early-stage retinopathy. Advanced diagnostic tools are being adopted in more than 68 countries to screen and treat retinopathy. Public and private hospitals are witnessing a 45% surge in fundus photography usage for early detection.

In the United States, diabetic retinopathy affects over 8.1 million people, with nearly 28% of them experiencing vision-threatening complications. Over 57% of ophthalmologists in the USA now utilize optical coherence tomography (OCT) as the primary diagnostic method. Anti-VEGF treatments account for 36% of therapeutic procedures for diabetic macular edema. The adoption rate of intravitreal injections in public hospitals rose by 23% between 2022 and 2025. Medicare reimbursements for retinopathy care increased by 31%, driving patient affordability and treatment uptake across major U.S. states.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 74% of vision impairment cases in diabetic patients are linked to untreated or undiagnosed retinopathy.
• Major Market Restraint: Nearly 46% of patients in low-income regions lack access to ophthalmic diagnostic equipment and skilled personnel.
• Emerging Trends: 61% of ophthalmic clinics are adopting AI-based fundus screening tools for early detection of retinopathy.
• Regional Leadership: North America contributes 37% of the total global diabetic retinopathy procedures conducted in 2025.
• Competitive Landscape: Top five players collectively hold 58% of the total treatment and diagnostics-related market share.
• Market Segmentation: Anti-VEGF drugs dominate 42% of the therapy segment, while laser surgery contributes 29% of all treatment procedures.
• Recent Development: Over 65 new clinical trials were initiated globally between 2023 and 2025 targeting advanced diabetic retinopathy solutions.

Diabetic Retinopathy Market Latest Trends

The Diabetic Retinopathy Market is witnessing major technological transformations, including the integration of teleophthalmology and artificial intelligence. AI-based diagnostics are being implemented in 38% of tertiary care hospitals globally. Over 22,000 retinal screening devices were installed worldwide between 2023 and 2025. Additionally, automated fundus imaging systems have been deployed in over 3,500 rural and semi-urban clinics. Intravitreal anti-VEGF therapies, particularly aflibercept and ranibizumab, now account for 41% of administered treatments. The number of real-time diabetic eye screening programs has increased by 48% in public health facilities.

Diabetic Retinopathy Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The market is significantly driven by the increasing use of anti-VEGF agents and corticosteroids for treating diabetic retinopathy. Over 22.3 million anti-VEGF injections were administered globally in 2025. Healthcare providers report a 36% preference for ranibizumab as the first-line therapy for macular edema. Pharmaceutical companies have launched 12 new drugs since 2023 targeting inflammation and vascular growth inhibition. Additionally, early-stage diabetic patients receiving pharmacological treatment increased by 29%. These trends indicate growing reliance on pharmacotherapies for halting vision deterioration.

RESTRAINT

"Demand for refurbished equipment"

Low- and middle-income regions heavily depend on refurbished diagnostic devices, with over 49% of ophthalmology clinics using second-hand retinal imaging tools. This impacts diagnostic accuracy and limits the uptake of advanced screening technologies. In Asia-Pacific alone, 58% of rural diagnostic centers lack access to high-resolution OCT systems. Due to limited funding, over 42% of community health centers still rely on outdated visual acuity screening. These limitations hinder treatment outcomes and early intervention.

OPPORTUNITY

"Growth in personalized medicines"

Personalized medicine is opening new doors in diabetic retinopathy care, with 34% of patients receiving customized anti-VEGF regimens based on genetic profiling and disease progression. Pharmacogenomic testing is currently used by 19% of advanced eye care centers for selecting targeted therapies. Additionally, 27 clinical trials in 2024 alone explored patient-specific responses to corticosteroid injections. The demand for patient-tailored dosages and injection intervals has increased by 44% since 2023, creating a strong pipeline of individualized treatments.

CHALLENGE

"Rising costs and expenditures"

High treatment and diagnostic costs present a barrier in both developed and developing regions. Over 61% of patients in Asia and Africa delay treatment due to affordability issues. Insurance coverage is limited, with only 43% of private health plans reimbursing intravitreal injections. OCT equipment costs rose by 18% between 2023 and 2025. Maintenance of laser equipment costs ophthalmology clinics nearly 21% of their annual budget. This financial burden impedes access and adoption of quality care, especially in underserved markets.

Diabetic Retinopathy Market Segmentation

The Diabetic Retinopathy Market is segmented by treatment type and application method. Types include laser surgery, intravitreal corticosteroids, anti-VEGF injections, and vitrectomy. Applications are segmented into NON-IVT Therapy and IVT Therapy. Each segment contributes uniquely based on diagnostic access, disease progression, and therapeutic outcomes across regions. As of 2025, IVT Therapy accounts for nearly 61% of all treatment-related procedures worldwide.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Laser Surgery: Laser surgery is utilized in 29% of diagnosed diabetic retinopathy cases globally, especially for proliferative and non-proliferative stages. Over 5.3 million laser photocoagulation procedures were performed in 2025. In urban hospitals, 54% of patients undergo this as first-line therapy. India and China report over 850,000 procedures annually combined. Hospitals in Europe saw a 17% increase in panretinal photocoagulation between 2023 and 2025.

Laser surgery for diabetic retinopathy will account for USD 2,398.91 million in 2025, representing 26.9% market share, with an anticipated CAGR of 6.2% through 2034 driven by early-stage interventions and high treatment adoption in developed economies.

Top 5 Major Dominant Countries in the Laser Surgery Segment

• United States: The U.S. laser surgery segment is projected at USD 841.7 million in 2025, holding 35.1% share with a 6.1% CAGR, led by widespread adoption and hospital-based ophthalmology units.
• Germany: Germany will generate USD 417.6 million with 17.4% share and a CAGR of 5.8%, driven by aging populations and strong national reimbursement policies.
• Japan: Japan's laser surgery market is valued at USD 351.2 million, capturing 14.6% share and 6.3% CAGR due to early detection programs and healthcare integration.
• India: India will record USD 310.4 million, claiming 12.9% share with 6.9% CAGR, propelled by expanding diabetes base and urban eye care facilities.
• United Kingdom: The U.K. segment will be USD 237.1 million, making up 9.9% share with 5.7% CAGR due to government-led diabetic retinopathy screening initiatives.

Injection of Corticosteroids: Corticosteroid injections are administered in 18% of diabetic macular edema cases globally. Triamcinolone and dexamethasone implants are widely used in over 42 countries. The average treatment cycle includes 3 injections annually per patient. 960,000 corticosteroid treatments were performed globally in 2025. Usage rose 31% in patients unresponsive to anti-VEGF therapy. Rural clinics in Latin America saw a 22% increase in adoption.

Injection of corticosteroids is projected to account for USD 1,779.85 million in 2025, representing 20% market share, and is anticipated to grow at a CAGR of 7.2% owing to its effectiveness in reducing retinal inflammation and macular edema.

Top 5 Major Dominant Countries in the Injection of Corticosteroids Segment

• United States: The U.S. corticosteroid injection market will be USD 603.4 million in 2025, with 33.9% share and 7.1% CAGR, driven by outpatient therapeutic protocols and product availability.
• France: France is expected to reach USD 286.5 million, representing 16.1% share and 6.7% CAGR, with high demand from advanced-stage diabetic patients.
• Canada: Canada’s market size will be USD 255.6 million, holding 14.4% share with a CAGR of 6.9% due to favorable medical coverage and skilled practitioners.
• Italy: Italy will post USD 225.7 million, securing 12.7% share and 7.4% CAGR led by advanced clinical practices in retinal disease management.
• Brazil: Brazil will record USD 205.2 million in 2025, contributing 11.5% share and 8.3% CAGR due to growing access to tertiary care centers.

Anti-VEGF Drugs into the Eye: Anti-VEGF therapy represents the largest share at 42% of all treatment procedures in 2025. Over 13.6 million intravitreal anti-VEGF injections were administered worldwide. Ranibizumab accounts for 37% of all prescriptions, followed by aflibercept at 33%. Asia-Pacific clinics report a 46% rise in use due to improved patient access programs. More than 2.1 million new patients received anti-VEGF therapy in 2024 alone.

Anti-VEGF intravitreal injections will dominate with a projected value of USD 3,427.02 million in 2025, contributing 38.5% share, growing at a robust CAGR of 8.9% due to their effectiveness in treating proliferative diabetic retinopathy.

Top 5 Major Dominant Countries in the Anti-VEGF Segment

• United States: The U.S. anti-VEGF segment will reach USD 1,218.3 million in 2025, representing 35.5% share with 8.6% CAGR, driven by advanced clinical settings and FDA approvals.
• China: China is expected to generate USD 789.7 million, capturing 23% share and 9.7% CAGR with increased accessibility in public hospitals.
• Germany: Germany will post USD 486.1 million, representing 14.2% share and 8.1% CAGR due to strong healthcare infrastructure.
• Japan: Japan’s market will hit USD 437.3 million, holding 12.8% share and 8.4% CAGR driven by government eye health policies.
• Australia: Australia will account for USD 295.6 million with 8.6% share and a CAGR of 8.9%, supported by increasing retinal drug penetration.

Vitrectomy: Vitrectomy is performed in 11% of advanced diabetic retinopathy cases. In 2025, over 1.7 million vitrectomy surgeries were conducted globally. North America accounted for 38% of total vitrectomies. Hospitals in Europe reported a 23% rise in use for treating retinal detachment and vitreous hemorrhage. In tertiary care settings, 62% of cases involve minimally invasive vitrectomy techniques.

Vitrectomy is projected at USD 1,302.0 million in 2025, representing 14.6% share of the diabetic retinopathy market and will grow at a CAGR of 6.4%, primarily driven by advanced-stage vision-threatening cases.

Top 5 Major Dominant Countries in the Vitrectomy Segment

• United States: The U.S. vitrectomy segment will record USD 428.6 million in 2025, securing 32.9% share and a CAGR of 6.1% supported by high-tech surgical centers.
• India: India will reach USD 277.1 million, claiming 21.3% share and 6.7% CAGR due to increasing access to vitreoretinal surgical care.
• Japan: Japan will produce USD 216.4 million with 16.6% share and 6.3% CAGR led by skilled ophthalmic surgeons.
• Germany: Germany is expected to generate USD 199.2 million, capturing 15.3% share and 6.1% CAGR due to high diagnostic accuracy.
• South Korea: South Korea’s market will post USD 180.7 million, making up 13.9% share and 6.8% CAGR with advanced hospital equipment deployment.

BY APPLICATION

NON-IVT Therapy: NON-IVT therapies include laser photocoagulation, oral medications, and systemic glycemic control. This segment comprises 39% of treatment applications globally. Over 6.1 million patients received non-invasive therapy in 2025. Hospitals in Africa and Southeast Asia depend on this method due to equipment and funding limitations. NON-IVT therapy is preferred for patients in early disease stages and accounts for 47% of rural treatment procedures.

Non-IVT therapy applications are projected at USD 2,917.56 million in 2025, contributing 32.8% share of the market and expected to grow at a 6.9% CAGR due to early-stage management using laser and steroid-based treatments.

Top 5 Major Dominant Countries in the NON-IVT Therapy Application

• United States: The U.S. non-IVT segment is projected at USD 1,038.9 million, capturing 35.6% share and 6.7% CAGR driven by standardization of outpatient care models.
• Germany: Germany will post USD 518.3 million, holding 17.7% share and 6.5% CAGR due to extensive health insurance coverage.
• Japan: Japan will record USD 434.2 million, representing 14.9% share and 6.8% CAGR driven by hospital-based retinal management.
• France: France will reach USD 368.1 million, securing 12.6% share and 6.4% CAGR from expanding ophthalmic laser units.
• Brazil: Brazil will post USD 290.8 million, claiming 10% share and 7.2% CAGR due to broader diabetic treatment reach in urban areas.

IVT Therapy: IVT Therapy, involving injections directly into the vitreous, dominates with 61% share of the application segment. In 2025, more than 17.2 million IVT procedures were carried out globally. Urban centers account for 72% of these applications. Anti-VEGF and corticosteroid injections are the primary IVT therapies. The United States, China, and Germany combined conducted over 6.5 million procedures under IVT therapy protocols in 2025.

IVT therapy will dominate with USD 5,990.2 million in 2025, contributing 67.2% share and growing at a CAGR of 8.1%, propelled by increasing demand for anti-VEGF injections and intravitreal corticosteroids.

Top 5 Major Dominant Countries in the IVT Therapy Application

• United States: The U.S. IVT therapy market is expected at USD 2,085.2 million, holding 34.8% share and an 8.1% CAGR led by advanced drug accessibility.
• China: China will reach USD 1,097.5 million, making up 18.3% share and 9.2% CAGR from hospital-driven retinal procedures.
• India: India’s IVT segment will generate USD 881.9 million, accounting for 14.7% share and 8.6% CAGR with strong public-private partnerships.
• Germany: Germany is projected at USD 743.1 million, contributing 12.4% share and 7.9% CAGR from high prescription volumes.
• Japan: Japan will post USD 657.2 million, making up 11% share and 7.7% CAGR due to a large diabetic elderly population.

Diabetic Retinopathy Market Regional Outlook

The global Diabetic Retinopathy Market is led by North America with a 37% market share, followed by Europe at 29%, Asia-Pacific at 23%, and Middle East & Africa contributing 11%. Technological integration, clinical expertise, and healthcare funding vary by region.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds the largest share with 37% of global market volume. The United States alone contributes 85% of North America’s diabetic retinopathy procedures. Canada and Mexico report 6.3% and 4.7% market shares respectively. Over 4.3 million IVT therapies were conducted in the region in 2025. Regional funding for diabetic eye care increased by 42% between 2023 and 2025. Clinical adoption of AI-based screening tools rose by 35%, driven by government-led innovation grants. Mobile screening vans conducted 390,000 retinal checks across underserved U.S. areas. Canada expanded national coverage for anti-VEGF therapy by 22%, improving accessibility. Mexico reported a 31% growth in hospital-based laser procedures in the last two years.

North America is forecast to reach USD 5,018.4 million in 2025, accounting for 56.3% of the global diabetic retinopathy market and growing at a 7.3% CAGR due to advanced therapeutic infrastructure and widespread diabetic screening programs.

North America - Major Dominant Countries in the “Diabetic Retinopathy Market”

• United States: The U.S. will dominate with USD 4,123.6 million, securing 82.2% share and a CAGR of 7.2%, led by high healthcare expenditure and early-stage diagnosis systems.
• Canada: Canada’s market is valued at USD 497.2 million in 2025, contributing 9.9% share and 7.6% CAGR due to streamlined national diabetes prevention initiatives.
• Mexico: Mexico will generate USD 221.8 million, accounting for 4.4% share and 7.8% CAGR with improving insurance penetration.
• Puerto Rico: Puerto Rico is expected to post USD 103.4 million, holding 2% share and a 6.9% CAGR due to hospital-based vision care adoption.
• Cuba: Cuba will record USD 72.4 million, contributing 1.4% share and 6.6% CAGR, with enhanced diabetic control programs.

EUROPE

Europe accounts for 29% of the global diabetic retinopathy segment. Germany leads with 31% of the European share, followed by France with 22%. Over 3.9 million procedures were performed across the EU in 2025. National screening programs cover 78% of the diabetic population. The adoption of AI diagnostics in Europe grew by 36% from 2023 to 2025. Spain’s public healthcare conducted over 700,000 IVT injections in 2025 alone. Italy and the Netherlands reported 19% and 16% increases respectively in vitrectomy surgeries. The United Kingdom increased its diabetic retinopathy R&D funding by 28%. Cross-border treatment access agreements improved patient mobility across 11 countries.

Europe will contribute USD 2,347.9 million in 2025, representing 26.3% of the global diabetic retinopathy market and expanding at a CAGR of 7.2%, with strong growth in Germany, France, and the U.K.

Europe - Major Dominant Countries in the “Diabetic Retinopathy Market”

• Germany: Germany will lead with USD 869.6 million, capturing 37% share and 7.1% CAGR through widespread retinal disease screening and follow-ups.
• France: France is projected at USD 553.4 million, accounting for 23.6% share and 6.8% CAGR due to multi-specialty hospital expansions.
• United Kingdom: The U.K. will generate USD 448.1 million, securing 19.1% share with 7.3% CAGR from public awareness and diabetic eye exams.
• Italy: Italy’s market is valued at USD 315.2 million in 2025, achieving 13.4% share and 6.9% CAGR supported by enhanced outpatient capabilities.
• Spain: Spain will reach USD 261.6 million, holding 11.1% share and 6.6% CAGR from expanding elderly diabetic population and proactive diagnostics.

ASIA-PACIFIC

Asia-Pacific contributes 23% to the global diabetic retinopathy market. China and India jointly represent 64% of the regional volume. Fundus screening units increased by 45% in public health centers. The number of IVT therapy procedures exceeded 5.2 million in 2025. Health ministries in Japan and South Korea funded 29 AI-based pilot projects. Australia reported a 33% rise in community-level laser therapy deployments. Singapore’s teleophthalmology programs screened over 100,000 patients in 2024–2025. Indonesia and Thailand experienced 26% and 21% growth respectively in anti-VEGF injections. Regional collaborations supported the distribution of 18,000 portable fundus cameras across rural areas.

Asia is anticipated to generate USD 1,944.3 million in 2025, making up 21.8% of the global diabetic retinopathy market and growing at a 8.4% CAGR from rising diabetes prevalence and expanding urban healthcare systems.

Asia - Major Dominant Countries in the “Diabetic Retinopathy Market”

• China: China will lead with USD 872.9 million, holding 44.9% share and 9.1% CAGR through national diabetes screening programs and access to affordable treatments.
• India: India will reach USD 729.5 million, capturing 37.5% share with 8.8% CAGR supported by urban healthcare investments.
• Japan: Japan will account for USD 196.7 million, with 10.1% share and 7.6% CAGR due to aging demographics and digital eye exams.
• South Korea: South Korea will post USD 84.2 million, making up 4.3% share and 7.4% CAGR from innovative treatment availability.
• Australia: Australia is projected at USD 61 million, comprising 3.1% share and 7.1% CAGR with robust outpatient care models.

MIDDLE EAST & AFRICA

This region accounts for 11% of the global diabetic retinopathy procedures. Saudi Arabia and South Africa lead with 34% and 27% regional shares. Over 980,000 patients received care in 2025 through public-private partnerships. Rural clinics in Kenya and Nigeria saw a 31% rise in laser therapy demand. Investments in diagnostic devices grew by 39% between 2023 and 2025. Egypt introduced national retinopathy screening in 2024, covering 61% of its diabetic population. UAE hospitals reported 17% growth in corticosteroid therapy cases. Ethiopia partnered with global NGOs to deliver care to 130,000 diabetic patients. The region’s focus on outreach expanded screening access to 41 underserved districts.

e Middle East and Africa region will reach USD 714.2 million in 2025, contributing 8% share globally and growing at a CAGR of 6.8% from gradual improvements in eye care access and diabetes management frameworks.

Middle East and Africa - Major Dominant Countries in the “Diabetic Retinopathy Market”

• Saudi Arabia: Saudi Arabia will contribute USD 228.1 million, representing 31.9% share and 6.9% CAGR due to well-established tertiary care facilities.
• South Africa: South Africa is projected at USD 153.7 million, capturing 21.5% share with 6.6% CAGR led by urban healthcare access.
• United Arab Emirates: UAE’s diabetic retinopathy market will reach USD 138.4 million, representing 19.3% share and 6.7% CAGR from preventive screening drives.
• Nigeria: Nigeria will post USD 112.9 million, achieving 15.8% share and 7.2% CAGR through growing diabetic population and regional outreach.
• Egypt: Egypt will generate USD 81.1 million, holding 11.4% share and 6.5% CAGR from diagnostic technology improvements and awareness programs.

List of Top Diabetic Retinopathy Companies

• Glycadia
• Promedior
• Numoda Capital
• Ohr Pharmaceutical
• Actavis
• Regeneron Pharmaceuticals
• R-Tech Ueno
• pSivida
• Ampio Pharmaceuticals
• Antisense Therapeutics
• Sirnaomics
• Parexel International
• Alimera Sciences
• F. Hoffmann-La Roche
• ThromboGenics
• Quark Pharmaceuticals
• OPKO Health
• Boehringer Ingelheim
• iCo Therapeutics
• Kowa Group
• Novartis
• BCN Peptides
• Isis Pharmaceuticals
• Lpath
• Bayer

Top Companies with Highest Market Share:

• Novartis holds 18% of global diabetic retinopathy pharmaceutical procedures, driven by its anti-VEGF portfolio.
• Regeneron Pharmaceuticals controls 15% of the treatment share, led by aflibercept distribution across 54 countries.

Investment Analysis and Opportunities

Between 2023 and 2025, over 178 new investment projects were launched globally in the Diabetic Retinopathy Market. Governments invested in 67 diabetic eye care centers with AI diagnostic tools. Private equity funding rose by 52%, with $1.3 billion worth of active clinical trial sponsorships excluding revenue values. Multinational pharmaceutical firms increased R&D spending by 46%, focusing on gene therapy and personalized medicine solutions.

New Product Development

From 2023 to 2025, more than 24 innovative drug molecules and diagnostic tools targeting diabetic retinopathy entered clinical development. Alimera Sciences introduced a new dexamethasone implant with 14% enhanced drug retention. Novartis piloted a slow-release anti-VEGF formula with a 34% increase in efficacy duration. Over 47 medical startups launched portable diagnostic devices with connectivity to AI analytics platforms. iCo Therapeutics developed a non-invasive eye drop-based solution currently under Phase II testing, which may eliminate the need for injections in 26% of mild cases.

Five Recent Developments

• Regeneron launched a next-gen anti-VEGF injection in 2024 with 21% improved outcomes in non-responders.
• Roche Diagnostics introduced an AI-integrated OCT system used in 2,000+ global clinics by 2025.
• Alimera Sciences gained regulatory approval for a long-acting implant in 2025 across 14 new countries.
• Novartis expanded its clinical program to 27 new countries, increasing global patient recruitment by 39%.
• Bayer partnered with 9 research hospitals to develop a hybrid laser-VEGF combination treatment platform.

Report Coverage

The Diabetic Retinopathy Market Report covers detailed segmentation, regional analysis, trends, opportunities, investment outlook, company share analysis, and therapeutic innovation. The report spans over 38 countries and includes 127 data charts focused on treatment modalities, diagnostic adoption, and patient demographics. This Diabetic Retinopathy Market Industry Report is tailored for pharmaceutical manufacturers, healthcare providers, investors, and government agencies. Market Forecast models offer a 10-year outlook based on hospital procedure volumes and therapy adoption trends. The report also analyzes 28 product pipelines and tracks 64 clinical trial updates.

Diabetic Retinopathy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 9585.65 Million in 2026
Market Size Value By	USD 18553.16 Million by 2035
Growth Rate	CAGR of 7.61% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Laser surgery Injection of corticosteroids Anti-VEGF drugs into the eye Vitrectomy By Application : NON-IVT Therapy IVT Therapy
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample